STOCK TITAN

Anterix (ATEX) executive sells 91K shares after exercising stock options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Anterix Inc. Chief Regulatory & Communications Officer Christopher Guttman-McCabe reported a combination of option exercises and share sales in Anterix common stock. On June 15, 2026, he exercised stock options to acquire a total of 122,852 common shares at strike prices between $25.75 and $49.39 per share.

On the same date, he executed open-market sales totaling 91,437 common shares at weighted average prices ranging from about $81.32 to $84.29 per share, across multiple price ranges noted in the footnotes. Following these transactions, one reported entry shows he directly owned 77,807 common shares. The filing also states that the option shares involved in these exercises were fully vested.

Positive

  • None.

Negative

  • None.
Insider Guttman-McCabe Christopher
Role Chief Reg & Comm Officer
Sold 91,437 shs ($7.54M)
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) 11,750 $0.00 --
Exercise Stock Option (Right to Buy) 8,000 $0.00 --
Exercise Stock Option (Right to Buy) 50,876 $0.00 --
Exercise Stock Option (Right to Buy) 20,000 $0.00 --
Exercise Stock Option (Right to Buy) 6,715 $0.00 --
Exercise Stock Option (Right to Buy) 25,511 $0.00 --
Exercise Common Stock 11,750 $25.75 $303K
Exercise Common Stock 8,000 $32.50 $260K
Exercise Common Stock 50,876 $34.40 $1.75M
Exercise Common Stock 20,000 $37.42 $748K
Exercise Common Stock 6,715 $42.14 $283K
Exercise Common Stock 25,511 $49.39 $1.26M
Sale Common Stock 35,321 $81.3236 $2.87M
Sale Common Stock 26,411 $82.2727 $2.17M
Sale Common Stock 16,381 $83.7233 $1.37M
Sale Common Stock 13,324 $84.2898 $1.12M
Holdings After Transaction: Stock Option (Right to Buy) — 0 shares (Direct, null); Common Stock — 58,142 shares (Direct, null)
Footnotes (1)
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.98 to $81.89, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.99 to $82.89, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.06 to $84.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.07 to $84.90, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote to this Form 4. The option shares are fully vested.
Shares sold 91,437 shares Open-market sales of Anterix common stock on June 15, 2026
Options exercised 122,852 shares Common shares acquired via option exercises on June 15, 2026
Sale prices $81.3236–$84.2898/share Weighted average prices for reported sale tranches
Strike prices $25.75–$49.39/share Exercise prices for the stock options converted
Shares held after 77,807 shares Direct common stock holdings shown after reported sales
Largest option block 50,876 shares at $34.40 Single option grant exercised into common stock
Net share direction -91,437 shares Net of reported buy/sell activity (sale vs. purchase codes)
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Stock Option (Right to Buy) financial
"security_title": "Stock Option (Right to Buy)""
derivative security financial
"transaction_code_description": "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
fully vested financial
"The option shares are fully vested."
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Guttman-McCabe Christopher

(Last)(First)(Middle)
3 GARRET MOUNTAIN PLAZA
SUITE 401

(Street)
WOODLAND PARK NEW JERSEY 07424

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Anterix Inc. [ ATEX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Reg & Comm Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/15/2026M11,750A$25.7558,142D
Common Stock06/15/2026M8,000A$32.566,142D
Common Stock06/15/2026M50,876A$34.4117,018D
Common Stock06/15/2026M20,000A$37.42137,018D
Common Stock06/15/2026M6,715A$42.14143,733D
Common Stock06/15/2026M25,511A$49.39169,244D
Common Stock06/15/2026S35,321D$81.3236(1)133,923D
Common Stock06/15/2026S26,411D$82.2727(2)107,512D
Common Stock06/15/2026S16,381D$83.7233(3)91,131D
Common Stock06/15/2026S13,324D$84.2898(4)77,807D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$25.7506/15/2026M11,750 (5)02/27/2027Common Stock11,750$00D
Stock Option (Right to Buy)$32.506/15/2026M8,000 (5)02/05/2028Common Stock8,000$00D
Stock Option (Right to Buy)$34.406/15/2026M50,876 (5)10/21/2030Common Stock50,876$00D
Stock Option (Right to Buy)$37.4206/15/2026M20,000 (5)02/28/2034Common Stock20,000$040,000D
Stock Option (Right to Buy)$42.1406/15/2026M6,715 (5)02/11/2029Common Stock6,715$00D
Stock Option (Right to Buy)$49.3906/15/2026M25,511 (5)05/17/2032Common Stock25,511$00D
Explanation of Responses:
1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.98 to $81.89, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote to this Form 4.
2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.99 to $82.89, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote to this Form 4.
3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.06 to $84.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote to this Form 4.
4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.07 to $84.90, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote to this Form 4.
5. The option shares are fully vested.
Remarks:
/s/ Gena L. Ashe06/17/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did Anterix (ATEX) report for Christopher Guttman-McCabe?

Anterix reported that Chief Regulatory & Communications Officer Christopher Guttman-McCabe exercised stock options for 122,852 common shares and sold 91,437 common shares in open-market transactions on June 15, 2026, at various weighted average sale prices around the low-to-mid $80s.

How many Anterix (ATEX) shares did the executive sell and at what prices?

Christopher Guttman-McCabe sold 91,437 Anterix common shares in open-market transactions. The weighted average sale prices ranged from about $81.32 to $84.29 per share, with footnotes explaining that each reported price reflects multiple trades within stated price ranges.

What stock options did the Anterix (ATEX) executive exercise in this Form 4?

He exercised options covering 122,852 Anterix common shares at strike prices of $25.75, $32.50, $34.40, $37.42, $42.14, and $49.39 per share. The filing notes that the option shares were fully vested at the time of exercise, converting derivative rights into common stock.

How many Anterix (ATEX) shares does Christopher Guttman-McCabe hold after these transactions?

After the reported sequence of option exercises and sales, one transaction line shows Christopher Guttman-McCabe directly owning 77,807 Anterix common shares. This figure comes from the "shares following transaction" column associated with the smallest post-sale balance in the non-derivative table.

Were the Anterix (ATEX) insider sales executed in single or multiple trades?

The sales were executed in multiple trades. The Form 4 footnotes state that each reported weighted average price reflects numerous individual transactions within specific price ranges, and that full trade-by-trade detail is available from the reporting person upon request.

What is the role of the insider involved in the Anterix (ATEX) Form 4 filing?

The insider is Christopher Guttman-McCabe, who serves as Anterix Inc.’s Chief Regulatory & Communications Officer. His Form 4 reports both the exercise of fully vested stock options and subsequent open-market sales of Anterix common stock on June 15, 2026.